Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.

[1]  R. McKelvie,et al.  Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. , 2008, The American journal of cardiology.

[2]  J. Cleland,et al.  Perception of symptoms is out of proportion to cardiac pathology in patients with “diastolic heart failure” , 2007, Heart.

[3]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[4]  L. Hatle.  How to diagnose diastolic heart failure a consensus statement. , 2007, European heart journal.

[5]  J. Cleland,et al.  Prognosis in heart failure with a normal ejection fraction. , 2007, The New England journal of medicine.

[6]  Erland Svensson,et al.  Natriuretic peptide biomarkers as information indicators in elderly patients with possible heart failure followed over six years: a head-to-head comparison of four cardiac natriuretic peptides. , 2007, Journal of cardiac failure.

[7]  W. Abhayaratna,et al.  Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. , 2006, American heart journal.

[8]  G. Ewald,et al.  N-terminal pro B-type natriuretic peptide levels: correlation with echocardiographically determined left ventricular diastolic function in an ambulatory cohort. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[9]  Y. Kihara,et al.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.

[10]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[11]  R. Rodeheffer,et al.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.

[12]  Dirk Westermann,et al.  The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. , 2005, European heart journal.

[13]  R. McKelvie,et al.  The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. , 2005, Journal of cardiac failure.

[14]  R. Valle,et al.  B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. , 2005, Journal of cardiac failure.

[15]  M. O’Donoghue,et al.  The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2005, Journal of cardiac failure.

[16]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[17]  R. Valle,et al.  The NT‐proBNP assay identifies very elderly nursing home residents suffering from pre‐clinical heart failure , 2005, European journal of heart failure.

[18]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[19]  M. Redfield,et al.  Epidemiology of diastolic heart failure. , 2005, Progress in cardiovascular diseases.

[20]  J. Sanderson.  BNP or echocardiography for monitoring heart failure? , 2004, European heart journal.

[21]  C. Vrints,et al.  Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. , 2004, European heart journal.

[22]  G. Aurigemma,et al.  Diastolic heart failure , 2004 .

[23]  K. Swedberg,et al.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. , 2004, European heart journal.

[24]  J. Parner,et al.  N‐terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF) , 2004, European journal of heart failure.

[25]  T. McDonagh,et al.  NT‐proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies , 2004 .

[26]  A. Larsson,et al.  Biochemical indicators of cardiac and renal function in a healthy elderly population. , 2004, Clinical biochemistry.

[27]  G. Habib,et al.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. , 2002, Circulation.

[28]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction , 2002 .

[29]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.

[30]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[31]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[32]  M. Emdin,et al.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure , 1998, Journal of endocrinological investigation.

[33]  K. Nakao,et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. , 1995, The Journal of clinical investigation.

[34]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[35]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[36]  D. Muthu,et al.  Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2009 .

[37]  이영주,et al.  원저 : 급성 호흡곤란 환자에서 우심부전과 좌심부전의 감별 진단: N-terminal probrain natriuretic peptide (NT-proBNP)의 의미 , 2007 .

[38]  渡邉 哲史.  Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure , 2006 .